File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use

TitleSafety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
Authors
Issue Date2018
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress 2018, Paris, France, 11-15 April 2018. In Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S87 How to Cite?
DescriptionOral Presentation: no. PS-156
Persistent Identifierhttp://hdl.handle.net/10722/253580
ISSN
2023 Impact Factor: 26.8
2023 SCImago Journal Rankings: 9.857
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGane, E-
dc.contributor.authorSeto, WKW-
dc.contributor.authorJanssen, H-
dc.contributor.authorCarantu, FA-
dc.contributor.authorKim, HJ-
dc.contributor.authorAbdurakhmanov, D-
dc.contributor.authorNishiguchi, S-
dc.contributor.authorAndrzej, H-
dc.contributor.authorBae, H-
dc.contributor.authorMo, S-
dc.contributor.authorSuri, V-
dc.contributor.authorGaggar, A-
dc.contributor.authorFlaherty, JF-
dc.contributor.authorKao, JH-
dc.contributor.authorBrunetto, M-
dc.contributor.authorFerret, MB-
dc.date.accessioned2018-05-21T02:59:55Z-
dc.date.available2018-05-21T02:59:55Z-
dc.date.issued2018-
dc.identifier.citationThe International Liver Congress 2018, Paris, France, 11-15 April 2018. In Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S87-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/253580-
dc.descriptionOral Presentation: no. PS-156-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.titleSafety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.doi10.1016/S0168-8278(18)30392-1-
dc.identifier.hkuros285071-
dc.identifier.volume68-
dc.identifier.issueSuppl. 1-
dc.identifier.spageS87-
dc.identifier.epageS87-
dc.identifier.isiWOS:000461068600175-
dc.publisher.placeNetherlands-
dc.identifier.issnl0168-8278-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats